Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Chen-Huang Center for EGFR-Mutant Lung Cancers aims to advance care and research of EGFR-mutant lung cancer with clinical trials of new and novel therapies supported by lab research and studies of cancer genetics.
Our trials include studies for patients with newly diagnosed EGFR-mutant lung cancer and patients whose cancer has advanced on current therapy, in addition to studies of cancer genetics.
A patient must meet certain requirements to participate in a clinical trial. Your doctor or another member of your health care team is the best resource for knowing your treatment options and eligibility.
For patients that are newly diagnosed or have not yet started treatment for EGFR-mutant lung cancer:
For patients that have had their EGFR-mutant lung cancer treated with targeted therapy already and have developed disease progression or relapse:
For patients that are newly diagnosed or have not yet started treatment for lung cancer with EGFR exon 20 insertion mutation:
For patients that have had their lung cancer with EGFR exon 20 insertion mutation treated and have developed disease progression or relapse:
New Patient Appointments
How Dana-Farber Cancer Discoveries Come to LifeDana-Farber’s Momentum of Discovery – Featuring Pasi A. Jänne, MD, PhD
(at left: Bruce Gilboard and Bethany Gilboard)
The Chen-Huang Center for EGFR-Mutant Lung Cancers partners with the Dana-Farber Psychosocial and Palliative Care Center through the generous support of the Bruce Gilboard Family Fund. The Bruce Gilboard Family Fund promotes increasing access to supportive
care for patients and caregivers throughout the continuum of care for EGFR-mutant lung cancer. This innovative pilot program will address the unique needs and challenges associated with treatment of EGFR-mutant lung cancer.
Learn more about this gift and how to support the Fund's mission